top of page
AVISI FOXC1 ImmunoHistoChemistry
Breast Cancer Test
TM
0
For in vitro diagnostic use *
A semi-quantitative immunohistochemical assay to determine FOXC1 protein over expression in formalin-fixed, paraffin-embedded (FFPE) breast carcinoma tissue routinely processed for histological evaluation using light microscopy.
The AVISI0™ FOXC1 (B2E3) murine monoclonal antibody is intended to assist in the diagnosis of invasive Basal-Like Breast Cancer (BLBC). The clinical interpretation of AVISI0™ FOXC1 staining or its absence should be evaluated using proper controls, cellular morphology, the patient's clinical history, and other diagnostic tests by qualified pathologists.
​
* Not available in the United States and certain countries throughout the world.
AVISI0™ FOXC1 ImmunoHistoChemistry
Breast Cancer Test
For in vitro diagnostics *
* Not available in the United States and certain countries throughout the world.
Genomic Research at the turn of the century established the existence of breast cancer molecular sub-types.
20-years later, the Basal-Like subtype still eludes detection.
Seamless Integration into Routine Laboratory Workflow
-
Utilizes existing standard equipment in histology lab.
-
Standard IHC protocols on FFPE samples.
-
Optimized for easy conversion and implementation onto automated IHC staining systems.
Easy to Interpret Microscopic Evaluation
-
Nuclear Stain vs Membrane Stain
-
Light Microscopy - Does not require added expense and complexities of fluorescent microscopy.
-
Industry accepted Allred scoring procedure slightly modified.
-
FOXC1 not expressed in the nucleus of normal breast tissue.
Modified Allred Score
bottom of page